Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL [NASD]
Exelixis, Inc.
Index- P/E83.95 EPS (ttm)0.20 Insider Own1.70% Shs Outstand312.47M Perf Week-2.04%
Market Cap5.26B Forward P/E19.01 EPS next Y0.88 Insider Trans-15.27% Shs Float306.54M Perf Month-8.70%
Income64.80M PEG- EPS next Q0.06 Inst Own85.50% Short Float3.61% Perf Quarter-29.95%
Sales1.03B P/S5.11 EPS this Y-65.50% Inst Trans0.23% Short Ratio4.92 Perf Half Y-26.62%
Book/sh6.12 P/B2.74 EPS next Y184.84% ROA3.10% Target Price- Perf Year-28.40%
Cash/sh3.78 P/C4.44 EPS next 5Y- ROE3.50% 52W Range16.19 - 27.35 Perf YTD-16.34%
Dividend- P/FCF34.73 EPS past 5Y19.70% ROI4.80% 52W High-38.61% Beta1.01
Dividend %- Quick Ratio6.60 Sales past 5Y92.70% Gross Margin96.10% 52W Low3.71% ATR0.68
Employees773 Current Ratio6.70 Sales Q/Q19.10% Oper. Margin5.10% RSI (14)36.61 Volatility2.74% 3.17%
OptionableYes Debt/Eq0.00 EPS Q/Q-96.80% Profit Margin6.30% Rel Volume1.25 Prev Close16.97
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout0.00% Avg Volume2.25M Price16.79
Recom1.90 SMA20-2.19% SMA50-15.67% SMA200-22.31% Volume2,809,065 Change-1.06%
Jun-15-21Initiated H.C. Wainwright Buy $47
May-18-21Resumed Goldman Sell $23
Mar-31-21Initiated Credit Suisse Outperform $30
Mar-12-21Initiated Wolfe Research Outperform $35
Mar-04-20Initiated Barclays Overweight $26
Jan-13-20Initiated SunTrust Buy $31
Nov-13-19Initiated BofA/Merrill Buy $22
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Aug-02-21 05:51AM  
Jul-29-21 03:05PM  
Jul-26-21 05:51AM  
Jul-22-21 04:05PM  
08:06AM  
Jul-19-21 02:45AM  
Jul-16-21 05:51AM  
Jul-13-21 10:10AM  
Jul-09-21 07:41AM  
06:55AM  
Jul-08-21 04:05PM  
Jul-02-21 05:51AM  
Jun-30-21 04:04PM  
Jun-29-21 07:03PM  
Jun-28-21 04:15PM  
12:04PM  
01:00AM  
Jun-18-21 08:00AM  
05:51AM  
Jun-15-21 11:39AM  
Jun-14-21 08:00AM  
Jun-07-21 08:00AM  
Jun-06-21 10:06AM  
Jun-04-21 09:00AM  
09:00AM  
09:00AM  
May-30-21 06:00AM  
May-26-21 04:15PM  
06:06AM  
May-25-21 10:51AM  
07:48AM  
May-24-21 04:05PM  
May-22-21 06:30AM  
May-21-21 06:31AM  
May-20-21 01:35AM  
May-09-21 02:06PM  
May-07-21 01:04PM  
11:30AM  
05:51AM  
May-06-21 07:05PM  
04:05PM  
03:15PM  
May-04-21 08:00AM  
Apr-27-21 04:05PM  
Apr-26-21 09:29AM  
Apr-25-21 06:00AM  
Apr-24-21 05:17AM  
Apr-22-21 04:05PM  
Apr-08-21 05:51AM  
Apr-06-21 12:33PM  
Apr-05-21 08:00AM  
Apr-01-21 12:21PM  
12:04PM  
Mar-31-21 01:01AM  
Mar-30-21 08:00AM  
Mar-27-21 06:45AM  
Mar-19-21 09:17AM  
08:41AM  
Mar-18-21 09:10AM  
08:00AM  
Mar-12-21 11:30AM  
Mar-10-21 03:08AM  
Mar-08-21 08:00AM  
Feb-26-21 06:30AM  
Feb-25-21 04:05PM  
08:00AM  
Feb-19-21 04:07PM  
Feb-17-21 06:06AM  
Feb-16-21 09:01AM  
Feb-13-21 01:00PM  
Feb-12-21 05:15PM  
Feb-11-21 03:00PM  
07:00AM  
Feb-10-21 05:55PM  
04:40PM  
04:05PM  
02:45PM  
Feb-09-21 04:08PM  
10:16AM  
07:13AM  
Feb-08-21 05:00PM  
05:00PM  
10:01AM  
Feb-04-21 04:05PM  
Feb-03-21 12:31PM  
Feb-01-21 08:00AM  
Jan-29-21 05:51AM  
Jan-27-21 04:05PM  
11:05AM  
Jan-25-21 09:24AM  
08:00AM  
Jan-22-21 07:44PM  
01:10PM  
Jan-11-21 09:48AM  
Jan-10-21 04:00PM  
06:06AM  
Jan-09-21 05:51AM  
Jan-04-21 04:05PM  
Dec-31-20 06:05AM  
Dec-28-20 01:51AM  
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres, Prod Dev & Med Aff & CMOJul 26Option Exercise4.2040,000168,000689,078Jul 28 08:06 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJul 21Option Exercise4.2035,000147,000649,078Jul 23 07:47 PM
Lamb PeterEVP, Scientific Strategy & CSOJul 15Option Exercise1.9060,000114,000449,467Jul 16 07:58 PM
Lamb PeterEVP, Scientific Strategy & CSOJul 15Sale17.4760,0001,048,200389,467Jul 16 07:58 PM
COHEN CHARLESDirectorJul 06Option Exercise4.7180,000377,200261,375Jul 08 07:45 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 17Option Exercise1.9060,000114,000449,467Jun 22 08:03 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 17Sale22.1860,0001,330,800389,467Jun 22 08:03 PM
Haley Patrick J.EVP, CommercialMay 18Sale24.7314,593360,885280,994May 18 08:13 PM
MARCHESI VINCENT TDirectorMay 14Option Exercise6.3040,000252,000106,115May 17 08:13 PM
POSTE GEORGEDirectorMay 14Sale24.9740,8021,018,826157,190May 17 08:11 PM
MARCHESI VINCENT TDirectorMay 14Sale25.0440,0001,001,60066,115May 17 08:13 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMay 13Option Exercise1.90100,000190,000714,078May 14 08:35 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMay 13Sale25.38100,0002,538,000614,078May 14 08:35 PM
MORRISSEY MICHAELPresident and CEOMay 12Option Exercise4.2050,000210,000541,813May 14 08:51 PM
PAPADOPOULOS STELIOSDirectorMay 11Option Exercise4.27120,000512,4001,293,600May 13 08:32 PM
PAPADOPOULOS STELIOSDirectorMay 11Sale24.9820,770518,7941,218,675May 13 08:32 PM
Freire Maria CDirectorMay 11Sale25.018,275206,95831,827May 17 08:15 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 26Option Exercise1.7050,00085,000663,482Apr 28 08:10 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 26Sale25.0050,0001,250,000613,482Apr 28 08:10 PM
Haley Patrick J.EVP, CommercialApr 26Sale25.037,665191,855297,392Apr 28 08:08 PM
Hessekiel JeffreyEVP and General CounselApr 26Sale25.0318,000450,540628,248Apr 28 08:06 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 01Option Exercise1.7050,00085,000663,482Apr 02 07:41 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 01Option Exercise1.7060,000102,000449,467Apr 02 07:51 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 01Sale23.0050,0001,150,000613,482Apr 02 07:41 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 01Sale22.9660,0001,377,600389,467Apr 02 07:51 PM
WYSZOMIERSKI JACK LDirectorMar 29Option Exercise3.3840,000135,200237,809Mar 31 09:02 PM
WYSZOMIERSKI JACK LDirectorMar 29Sale22.646,220140,821231,589Mar 31 09:02 PM
Garber Alan MDirectorMar 15Option Exercise3.3840,000135,20052,718Mar 17 08:11 PM
Garber Alan MDirectorMar 15Sale23.6040,000944,00012,718Mar 17 08:11 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise1.7065,000110,500405,072Mar 03 07:49 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1165,0001,437,150340,072Mar 03 07:49 PM
COHEN CHARLESDirectorFeb 24Option Exercise3.3840,000135,200221,375Feb 26 08:10 PM
COHEN CHARLESDirectorFeb 24Sale22.6940,000907,600181,375Feb 26 08:10 PM
WILLSEY LANCEDirectorFeb 23Option Exercise3.3840,000135,200464,415Feb 24 08:11 PM
WILLSEY LANCEDirectorFeb 23Sale21.9340,000877,136424,415Feb 24 08:11 PM
POSTE GEORGEDirectorFeb 22Option Exercise3.3840,000135,200197,992Feb 24 08:18 PM
MARCHESI VINCENT TDirectorFeb 22Sale22.2924,097537,12266,115Feb 24 08:15 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 18Option Exercise1.7050,00085,000590,597Feb 19 07:57 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 18Sale22.3550,0001,117,500540,597Feb 19 07:57 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 17Option Exercise1.7050,00085,000590,597Feb 19 07:57 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 17Sale22.5050,0001,125,000540,597Feb 19 07:57 PM
FELDBAUM CARL BDirectorFeb 16Option Exercise3.3820,00067,60028,521Feb 17 08:03 PM
WILLSEY LANCEDirectorFeb 16Sale21.9050,0001,095,000424,415Feb 24 08:11 PM
FELDBAUM CARL BDirectorFeb 16Sale21.9620,000439,2008,521Feb 17 08:03 PM
Haley Patrick J.EVP, CommercialFeb 12Sale21.5745,000970,650246,887Feb 17 08:15 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise1.7065,000110,500348,124Feb 03 07:57 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale22.0865,0001,435,200283,124Feb 03 07:57 PM
Senner Christopher J.EVP and CFOJan 12Option Exercise3.6630,000109,800275,596Jan 14 08:22 PM
Senner Christopher J.EVP and CFOJan 12Sale25.0030,000750,000245,596Jan 14 08:22 PM
Hessekiel JeffreyEVP and General CounselJan 04Option Exercise5.1250,000256,100541,754Jan 06 08:22 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 04Option Exercise1.7065,000110,500348,124Jan 06 08:40 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 04Sale20.3265,0001,320,800283,124Jan 06 08:40 PM
Lamb PeterEVP, Scientific Strategy & CSODec 18Option Exercise1.7065,000110,500348,124Dec 22 07:58 PM
Lamb PeterEVP, Scientific Strategy & CSODec 18Sale20.0165,0001,300,650283,124Dec 22 07:58 PM
WILLSEY LANCEDirectorDec 04Option Exercise5.82106,142617,746474,415Dec 04 07:56 PM
MARCHESI VINCENT TDirectorNov 24Option Exercise5.8240,004232,823130,216Nov 25 07:46 PM
MARCHESI VINCENT TDirectorNov 24Sale18.5040,004740,07490,212Nov 25 07:46 PM
Hessekiel JeffreyEVP and General CounselNov 15Option Exercise7.2730,000218,100494,254Nov 17 08:00 PM
WYSZOMIERSKI JACK LDirectorNov 10Option Exercise5.8262,403363,185231,809Nov 13 08:18 PM
WYSZOMIERSKI JACK LDirectorNov 10Sale20.6134,000700,740197,809Nov 13 08:18 PM
Hessekiel JeffreyEVP and General CounselOct 21Option Exercise7.2739,742288,924382,768Oct 23 08:08 PM
Hessekiel JeffreyEVP and General CounselOct 21Sale21.9539,742872,337343,026Oct 23 08:08 PM
Senner Christopher J.EVP and CFOOct 08Option Exercise3.6610,00036,600137,882Oct 09 08:04 PM
Senner Christopher J.EVP and CFOOct 08Sale25.0010,000250,000127,882Oct 09 08:04 PM
Hessekiel JeffreyEVP and General CounselSep 22Option Exercise7.2710,25874,576353,284Sep 24 08:03 PM
Hessekiel JeffreyEVP and General CounselSep 22Sale26.1410,258268,144343,026Sep 24 08:03 PM
Haley Patrick J.EVP, CommercialSep 21Option Exercise5.824,68027,238120,251Sep 23 08:12 PM
Haley Patrick J.EVP, CommercialSep 21Sale26.094,680122,101115,571Sep 23 08:12 PM
Hessekiel JeffreyEVP and General CounselSep 16Option Exercise7.2720,000145,400363,026Sep 16 08:24 PM
Hessekiel JeffreyEVP and General CounselSep 16Sale26.1120,000522,200343,026Sep 16 08:24 PM
Senner Christopher J.EVP and CFOSep 15Option Exercise3.6620,00073,200147,882Sep 15 08:03 PM
Senner Christopher J.EVP and CFOSep 15Sale25.0020,000500,000127,882Sep 15 08:03 PM
Hessekiel JeffreyEVP and General CounselSep 08Option Exercise5.18249,6921,293,315503,692Sep 10 08:39 PM
COHEN CHARLESDirectorSep 01Option Exercise5.82115,396671,605181,375Sep 03 08:05 PM
POSTE GEORGEDirectorAug 14Option Exercise5.8229,662172,633157,992Aug 14 07:50 PM